RevBio

Focus: RevBio is a pre-revenue biotech company headquartered in Lowell, MA focused on developing Tetranite, a biocompatible bone adhesive platform with applications across orthopedic surgery, craniotomy, and dental procedures.

Oncology Musculoskeletal

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About RevBio

AI assessmentNot Hiring

No open roles listed right now. Follow RevBio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Augmented with Tetranite Bone Adhesive

AO/OTA Type 2R3C Distal Radius Fracture

N/A

Clinical Trials (1)

NCT07452536A Pilot Clinical Study to Evidence Safety and Efficacy of Fracture Fixation of the Distal Radius Using a Bioresorbable Bone Adhesive to Augment Metal Hardware

N/A

Help build intelligence for RevBio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on differentiated hardware-adhesive technology in large unmet markets (orthopedic fixation, cranial reconstruction, dental implants)
Early-stage platform with multiple clinical programs providing exposure to program development and regulatory strategy across multiple indications
Potential for meaningful equity upside if Tetranite demonstrates clinical utility and achieves commercialization

Watch Out For

Zero revenue, no approved products, and minimal disclosed funding means pre-commercial financial runway is uncertain and restructuring risk is high
No active job postings and sparse public information suggest a very small team with limited near-term hiring and career trajectory visibility
All programs reported as 'N/A' phase with only 6 small trials total indicates very early development stage—long path to value realization

Generated by Claude from RevBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Tetranite for Cranial Flap Fixation

Craniotomy

N/A

Clinical Trials (1)

NCT06780852A Pilot Clinical Study to Evidence Improved Cranial Flap Fixation With a Bioresorbable Bone Adhesive

N/A

Tetranite

Adhesive Dental

N/A

Clinical Trials (1)

NCT04121364Immediate Placement and Stabilization of Dental Implants With Tetranite Stabilization Material in Mandibular and Maxillary Tooth Extraction Sites That Fail to Provide Adequate Primary Stability

N/A

Tetranite for Cranial Flap Fixation

Craniotomy

N/A

Clinical Trials (1)

NCT07452549Safety and Effectiveness of TETRANITE Bone Adhesive for Cranial Flap Fixation Compared to Traditional Metal Hardware

N/A

Tetranite Implant Stabilization Material

Adhesive Dental

N/A

Clinical Trials (1)

NCT05535426Feasibility Study to Assess Outcomes of Immediately Inserted and Restored Dental Implants Using pH-modified Tetranite

N/A

Tetranite for Cranial Flap Fixation

Craniotomy

N/A

Clinical Trials (1)

NCT06095531A Pilot Study to Evidence Improved Cranial Flap Fixation With a Bioresorbable Bone Adhesive

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 6 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo